{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-014284","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2024-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.899026+00:00","generated_at":"2026-06-04T00:13:39.983901+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Imunon regains Nasdaq minimum bid price compliance, deficiency resolved","bullets":["Nasdaq notified Imunon on April 10, 2024, that compliance with Listing Rule 5550(a)(2) was regained after 10 consecutive trading days with bid price over $1.00.","The deficiency notice from December 26, 2023, is now fully resolved; stock maintains listing on Nasdaq Capital Market under symbol IMNN.","Executive Chairman notes topline results from OVATION 2 Study for IMNN-001 in advanced ovarian cancer expected mid-2024.","Company plans to begin Phase 1 study of COVID-19 booster vaccine (IMNN-101) in Q2 2024 after FDA IND clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-014284","json":"https://secwatch.observer/filing/0001493152-24-014284.json","markdown":"https://secwatch.observer/filing/0001493152-24-014284.md","text":"https://secwatch.observer/filing/0001493152-24-014284.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315224014284/0001493152-24-014284-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315224014284/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:13:39.983901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}